Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 2.00 is 12% below its 5-year average of 2.27, around the middle of its 5-year range (0.53–4.04).
As of the fiscal period ended Tuesday, June 30, 2026. 20.96% below its 12-month average of 2.53.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.00.
CURRENT RATIO
2.00
CURRENT RATIO AVG TTM
2.53
CURRENT RATIO AVG 3Y
2.08
CURRENT RATIO AVG 5Y
2.27
CURRENT RATIO AVG 10Y
2.32
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-20.96%
CURRENT VS 3Y AVG
-3.92%
CURRENT VS 5Y AVG
-12.13%
CURRENT VS 10Y AVG
-13.74%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.36
median of 529 covered companies
CURRENT VS SECTOR MEDIAN
-40.56%
vs the sector median at left
Insight Molecular Diagnostics Inc.
Market Cap
$120.80M
Current Ratio
2.00
TTM Avg
2.53
3Y Avg
2.08
5Y Avg
2.27
Market Cap
$119.09M
Current Ratio
0.18
TTM Avg
2.23
3Y Avg
2.69
5Y Avg
2.63
Market Cap
$118.52M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$123.26M
Current Ratio
10.21
TTM Avg
11.59
3Y Avg
10.00
5Y Avg
8.96
Market Cap
$116.84M
Current Ratio
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$115.66M
Current Ratio
12.63
TTM Avg
12.83
3Y Avg
15.22
5Y Avg
15.22
Market Cap
$114.76M
Current Ratio
13.55
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
Market Cap
$114.47M
Current Ratio
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $120.80M | 2.00 | 2.53 | 2.08 | 2.27 |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.18 | 2.23 | 2.69 | 2.63 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | 6.49 | 6.44 | 8.52 | 8.53 |
| Genelux Corporation (GNLX)vs › | $117.03M | 2.39 | 3.50 | 2.69 | 1.97 |
| enGene Holdings Inc. (ENGN)vs › | $123.26M | 10.21 | 11.59 | 10.00 | 8.96 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | 3.36 | 3.23 | 4.24 | 6.08 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | 12.63 | 12.83 | 15.22 | 15.22 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | 13.55 | 17.30 | 10.78 | 9.73 |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | 13.40 | 10.04 | 7.53 | 8.95 |
| Lucid Diagnostics Inc. (LUCD)vs › | $111.89M | 1.33 | 1.19 | 1.50 | 3.26 |
Current Ratio
2.00
Quick Ratio
1.98
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 2.00 |
| 2026-03-31 | 2.54 |
| 2025-12-31 | 1.27 |
| 2025-09-30 | 2.79 |
| 2025-06-30 | 4.04 |
| 2025-03-31 | 3.75 |
| 2024-12-31 | 1.62 |
| 2024-09-30 | 0.53 |
| 2024-06-30 | 1.38 |
| 2024-03-31 | 0.78 |
| 2023-12-31 | 1.49 |
| 2023-09-30 | 2.11 |
| 2023-06-30 | 2.74 |
| 2023-03-31 | 1.66 |
| 2022-12-31 | 2.11 |
| 2022-09-30 | 2.83 |
| 2022-06-30 | 3.49 |
| 2022-03-31 | 1.76 |
| 2021-12-31 | 2.77 |
| 2021-09-30 | 3.56 |
| 2021-06-30 | 2.53 |
| 2021-03-31 | 6.49 |
| 2020-12-31 | 1.03 |
| 2020-09-30 | 1.35 |
| 2020-06-30 | 2.70 |
| 2020-03-31 | 2.62 |
| 2019-12-31 | 5.17 |
| 2019-09-30 | 6.66 |
| 2019-06-30 | 9.13 |
| 2019-03-31 | 12.82 |
| 2018-12-31 | 1.55 |
| 2018-09-30 | 2.58 |
| 2018-06-30 | 2.54 |
| 2018-03-31 | 2.57 |
| 2017-12-31 | 1.91 |
| 2017-09-30 | 2.69 |
| 2017-06-30 | 2.19 |
| 2017-03-31 | 2.96 |
| 2016-12-31 | 2.97 |
| 2016-09-30 | 3.85 |
| 2016-06-30 | 2.12 |
| 2016-03-31 | 2.87 |
| 2015-12-31 | 4.72 |
| 2015-09-30 | 5.85 |
| 2015-06-30 | 2.81 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.49 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
